|4Nov 18, 8:30 AM ET

Shemesh Shay 4

4 · Nuvectis Pharma, Inc. · Filed Nov 18, 2022

Insider Transaction Report

Form 4
Period: 2022-11-16
Shemesh Shay
Chief Dev. & Ops. Officer
Transactions
  • Purchase

    Common Stock

    2022-11-16$7.10/sh+150$1,0651,245,215 total
  • Purchase

    Common Stock

    2022-11-17$7.20/sh+150$1,0801,245,365 total
Footnotes (1)
  • [F1]Includes 48,399 shares of restricted stock and 60,000 restricted stock units.

Documents

1 file
  • 4
    tm2230911-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT